Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc.

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Today, 1/28/2026, According to Top Analysts

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apogee Therapeutics (APGE – Research Report) and Neurocrine (NBIX...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (APGE) and Neurocrine (NBIX)

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Neurocrine, with a price target of $178.00. Verma covers the Healthca...

UBS Reaffirms Their Buy Rating on Neurocrine (NBIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SOPHiA GENETICS (SOPH – Research Report), Verastem (...

Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Medline, Inc...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Medline, Inc. Class A (MDLN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Climb Bio (C...

Current Quarter	$1.81	Next Quarter	$1.29
Current Year	$5.21	Next Year	$6.97
QoQ Growth	-28.7%	YoY Growth	+33.8%
3Y EPS CAGR	+53.0%	Target Price	$178.31
Consensus	Buy	Upside	+28.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NBIX	$139.15	+1.10%	550.78K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NBIX	$139.15	+1.1%	550.78K
3
4
5
6

NBIX

NBIX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Neurocrine Biosciences Inc. Data in Excel

Get Neurocrine Biosciences Inc. Data in Excel